Vascepa is a prescription medication used to lower triglyceride levels in adults with severe hypertriglyceridemia, a condition in which the blood contains high levels of triglycerides. Unlike traditional statins, which lower cholesterol levels, Vascepa specifically targets triglycerides.

Vascepa contains the active ingredient icosapent ethyl, which is a highly purified form of eicosapentaenoic acid (EPA), a type of omega-3 fatty acid. EPA is known to have anti-inflammatory properties and can reduce the production of triglycerides in the liver.

Traditional statins, on the other hand, work by blocking the enzyme HMG-CoA reductase, which is involved in the production of cholesterol in the liver. By lowering cholesterol levels, statins can reduce the risk of heart disease and stroke.

While both Vascepa and statins can be used to reduce the risk of cardiovascular disease, they work in different ways and target different lipid levels. Vascepa is specifically indicated for patients with severe hypertriglyceridemia, while statins are typically prescribed for patients with high cholesterol levels.

It is important to note that Vascepa should not be used as a substitute for statins or other lipid-lowering therapies. Patients should work with their healthcare provider to determine the best treatment plan for their individual needs.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.medicalnewstoday.com/articles/drugs-vascepa
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4671468/